```html

Pterygium – A Complete Patient‑Friendly Guide

Overview

A pterygium (pronounced “per‑ti‑JEE‑um”) is a benign, wedge‑shaped growth of fibro‑vascular tissue that originates from the conjunctiva (the thin, transparent membrane covering the white part of the eye) and extends onto the cornea. Although non‑cancerous, a pterygium can cause irritation, blurry vision, and cosmetic concerns.

Who it affects: The condition most commonly appears in adults between the ages of 30 and 60, but it can develop in younger people with intense UV exposure. It is slightly more prevalent in men than women, possibly because of occupational sun exposure differences.

Prevalence: Worldwide studies estimate that 10–30 % of people living in sunny, low‑latitude regions develop a pterygium, compared with 2–5 % in higher‑latitude, cooler climates. In the United States, approximately 3‑5 % of the adult population is affected, with higher rates among outdoor workers, farmers, and fishermen (Mayo Clinic, 2023; WHO, 2022).

Symptoms

Symptoms can range from completely asymptomatic to significant visual disturbance. Common complaints include:

• Redness and irritation – a gritty, burning, or foreign‑body sensation.
• Itching or tearing – especially in windy or dusty conditions.
• Visible growth – a fleshy, triangular tissue extending from the conjunctiva toward the cornea, often on the nasal side of the eye.
• Blurred or decreased vision – occurs when the growth reaches the central cornea and distorts the surface.
• Photophobia – increased sensitivity to bright light.
• Dry eye symptoms – the pterygium can disrupt the tear film.
• Astigmatism – irregular corneal curvature caused by the lesion, leading to distorted images.
• Cosmetic concern – many patients seek treatment for the unsightly appearance.

Causes and Risk Factors

Primary cause

The exact pathogenesis is not fully understood, but the leading theory attributes pterygium formation to chronic ultraviolet (UV) radiation damage to the ocular surface. UV light induces DNA damage, oxidative stress, and inflammation, prompting fibrovascular tissue proliferation.

Key risk factors

• Sunlight exposure – especially UV‑A (320‑400 nm) and UV‑B (280‑320 nm). Outdoor occupations (farming, fishing, construction) increase risk dramatically (relative risk ≈ 3–5).
• Geographic location – living near the equator, at high altitude, or in arid climates where UV intensity is greater.
• Age – cumulative UV exposure over decades raises risk.
• Male gender – possibly due to occupational differences.
• Dry eye disease – an unhealthy ocular surface may predispose to fibrovascular growth.
• Chronic ocular irritation – dust, wind, smoke, or chemicals can act as cofactors.
• Genetic predisposition – family studies suggest a modest hereditary component.

Diagnosis

Diagnosis is usually clinical, based on a careful eye examination.

Steps in evaluation

1. History taking – duration, symptom pattern, occupational sun exposure, use of protective eyewear.
2. Visual acuity test – assesses any impact on vision.
3. Slit‑lamp biomicroscopy – the gold standard. The clinician visualizes the size, vascularity, and extent of tissue on the cornea.
4. Photographic documentation – standardized photos help monitor growth over time.
5. Corneal topography or keratometry – measures induced astigmatism when the lesion is near the visual axis.

If atypical features (e.g., rapid growth, discoloration) are present, a biopsy may be performed to rule out dysplasia or rare malignant transformation (conjunctival intraepithelial neoplasia). However, this is uncommon.

Treatment Options

Management depends on symptom severity, lesion size, and impact on vision.

1. Conservative (non‑surgical) measures

• Artificial tears – lubricate the ocular surface and reduce irritation.
• Topical anti‑inflammatory drops (e.g., cyclosporine 0.05 % or low‑dose steroids) can diminish redness and mild swelling.
• Sunscreen eyewear – UV‑blocking sunglasses (≥ 99 % UV‑A/UV‑B protection) and wide‑brim hats are essential preventive tools.
• Cold compresses – provide short‑term relief of burning sensation.

2. When surgery is indicated

Indications include:

• Progressive growth toward the visual axis
• Corneal involvement causing vision loss or astigmatism
• Persistent discomfort unresponsive to medical therapy
• Cosmetic concerns affecting quality of life

Surgical techniques

1. Excisional surgery with conjunctival autograft (gold standard) – the pterygium is removed and a piece of the patient’s own conjunctiva, harvested from the superior bulbar area, is sutured or glued into place. Recurrence rates are 5–10 %.
2. Amniotic membrane transplantation – useful when autograft tissue is limited; recurrence 12–20 %.
3. Adjunctive anti‑mitotic therapy – intra‑operative application of mitomycin‑C (0.02–0.04 %) reduces recurrence but carries a small risk of scleral thinning.
4. Limbal stem‑cell transplantation – reserved for recurrent or aggressive cases.

Post‑operative care

• Topical antibiotics for 1 week to prevent infection.
• Short course of steroid eye drops (e.g., prednisolone acetate 1 %) tapered over 4–6 weeks to control inflammation.
• Continued UV protection – failure to wear sunglasses after surgery dramatically increases recurrence (up to 30 %).

Living with Pterygium

Even after successful treatment, many patients need ongoing care to keep symptoms at bay.

• UV protection every day – wear wrap‑around sunglasses and a wide‑brimmed hat, even on cloudy days.
• Artificial tears – keep a bottle handy; use preservative‑free drops if you need frequent dosing.
• Environmental control – use humidifiers in dry climates, avoid wind‑blowing directly at the eyes, and wear protective goggles when working with dust or chemicals.
• Regular eye exams – at least once a year, or sooner if you notice new irritation or vision change.
• Monitor for recurrence – watch for any new pinkish tissue, redness, or worsening vision.

Prevention

Because UV exposure is the primary driver, preventive strategies are straightforward and highly effective.

1. UV‑blocking sunglasses – Choose lenses that block 100 % UV‑A and UV‑B; wrap‑around styles reduce peripheral exposure.
2. Wide‑brimmed hats – A brim of at least 3 inches shade the eyes and eyelids.
3. Limit midday sun – If possible, avoid outdoor activities between 10 a.m. and 4 p.m. when UV intensity peaks.
4. Lubricating eye drops – Regular use can maintain a healthy tear film, decreasing chronic irritation.
5. Smoking cessation – Smoking exacerbates ocular surface inflammation.

Complications

While a pterygium is benign, untreated or poorly managed cases can lead to:

• Reduced visual acuity – direct corneal involvement or induced astigmatism.
• Corneal scarring – permanent opacity if the lesion invades the central cornea.
• Recurrent inflammation – chronic redness, tearing, and photophobia.
• Rare malignant transformation – conjunctival intraepithelial neoplasia or squamous cell carcinoma (<0.5 % of cases); vigilance is essential.
• Recurrence after surgery – up to 30 % in patients who do not use UV protection post‑operatively.

When to Seek Emergency Care

References

• Mayo Clinic. Pterygium: Symptoms & Causes. 2023.
• World Health Organization. UV Radiation and Eye Health. 2022.
• Centers for Disease Control and Prevention. Preventing UV‑Related Eye Injuries. 2021.
• Cleveland Clinic. Pterygium. Updated 2024.
• Uçar A, et al. “Recurrence rates after pterygium surgery with adjunctive mitomycin‑C.” *Ophthalmic Surgery*, 2020.
• Shin JH, et al. “Long‑term outcomes of conjunctival autograft for pterygium.” *American Journal of Ophthalmology*, 2022.

```